Literature DB >> 10510436

Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation.

P G McLean1, M Perretti, A Ahluwalia.   

Abstract

1 We have investigated the role of kinin B1 receptor induction in the endotoxemic rat heart and elucidated the mechanisms underlying B1 receptor-mediated coronary vasodilation. We also investigated the role of these receptors in endotoxin-induced hypotension. 2 Endotoxin treatment induced cardiac B1 receptor mRNA expression and promoted a coronary vasodilation response to des-Arg9bradykinin (DABK; ED50 = 149.4 pmol, n = 9) ex vivo peaking at 6 h. The B1 receptor antagonist des-Arg9-[Leu8]-BK (DALBK, 30 nM) significantly (P<0.05) inhibited the DABK-induced response (pA2 = 8.4, n = 5) whilst HOE140 (B2 receptor antagonist, 10 nM) was inactive (n = 4). 3 Removal of the endothelium or infusion with indomethacin (5 microM), but not L-NAME (300 microM) or ODQ (1 microM), inhibited (>85%, P<0.05, n = 5) the DABK-induced response. DABK caused a dose-dependent release of the prostacyclin metabolite, 6-keto-PGF1a (Emax = 0.3 ng ml-1, n = 6). 4 In vitro perfusion of hearts with endotoxin (1 microg ml-1, n = 6) or interleukin-1beta (5 ng ml-1, n = 6) induced B1 receptor mRNA expression and promoted a time-dependent vasodilation response to DABK. 5 Endotoxin treatment (6 h) in vivo promoted a hypotensive response to DABK (ED50 = 29.7 nmol kg-1, n = 10) which was antagonised by DALBK (3-6 nmol kg-1 min-1, P<0.05, n = 7). DALBK (3 nmol kg-1 min-1) and des-Arg10HOE140 (B1 receptor antagonist, 30 nmol kg-1 min-1) produced a 5.3% (n = 6, P<0.05) and 8.8% (n = 5, P<0.05) reversal, respectively, of endotoxin-induced hypotension. 6 In summary, we have shown that in endotoxemia activation of B1 receptors causes coronary vasodilation via endothelial prostacyclin release. Additionally, B1 receptor antagonists partially reversed endotoxin-induced hypotension. Therefore activation of B1 receptors may have a role to play in the vascular changes associated with endotoxemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510436      PMCID: PMC1571626          DOI: 10.1038/sj.bjp.0702743

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Mechanism of actions of sumatriptan on coronary flow before and after endothelial dysfunction in guinea-pig isolated heart.

Authors:  A J Ellwood; M J Curtis
Journal:  Br J Pharmacol       Date:  1997-03       Impact factor: 8.739

2.  Nitric oxide synthase is not involved in cardiac contractile dysfunction in a rat model of endotoxemia without shock.

Authors:  X Meng; L Ao; J M Brown; D A Fullerton; A Banerjee; A H Harken
Journal:  Shock       Date:  1997-02       Impact factor: 3.454

Review 3.  The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock.

Authors:  M P Glauser
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Kinin receptors in human vascular tissue: their role in atheromatous disease.

Authors:  D M Raidoo; R Ramsaroop; S Naidoo; W Müller-Esterl; K D Bhoola
Journal:  Immunopharmacology       Date:  1997-06

5.  Induction of bradykinin B1 hypotensive receptors in rats by lipopolysaccharide.

Authors:  M Nicolau; M R Feltrin; D Regoli
Journal:  Can J Physiol Pharmacol       Date:  1996-03       Impact factor: 2.273

Review 6.  Pharmacology of bradykinin and related kinins.

Authors:  D Regoli; J Barabé
Journal:  Pharmacol Rev       Date:  1980-03       Impact factor: 25.468

7.  Dual role for nitric oxide in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats.

Authors:  J G Filep; A Delalandre; M Beauchamp
Journal:  Circ Res       Date:  1997-11       Impact factor: 17.367

8.  Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

Authors:  A M Fein; G R Bernard; G J Criner; E C Fletcher; J T Good; W A Knaus; H Levy; G M Matuschak; H M Shanies; R W Taylor; T C Rodell
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

9.  Characterisation of bradykinin receptors from juvenile pig coronary artery.

Authors:  D Pruneau; J M Luccarini; E Defrêne; J L Paquet; P Bélichard
Journal:  Eur J Pharmacol       Date:  1996-02-15       Impact factor: 4.432

10.  Relaxation of isolated mesenteric arteries by des-Arg9-bradykinin stimulation of B1 receptors.

Authors:  L Churchill; P E Ward
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

View more
  14 in total

Review 1.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

2.  Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors.

Authors:  Vanessa F Merino; Mihail Todiras; Luciana A Campos; Vera Saul; Elena Popova; Ovidiu C Baltatu; João B Pesquero; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2008-04-19       Impact factor: 4.599

3.  Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects.

Authors:  D deBlois; R A Horlick
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Non-competitive pharmacological antagonism at the rabbit B(1) receptor.

Authors:  J F Larrivée; L Gera; S Houle; J Bouthillier; D R Bachvarov; J M Stewart; F Marceau
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Exacerbation of DSS-induced colitis in mice lacking kinin B(1) receptors through compensatory up-regulation of kinin B(2) receptors: the role of tight junctions and intestinal homeostasis.

Authors:  R Marcon; R F Claudino; R C Dutra; A F Bento; E C Schmidt; Z L Bouzon; R Sordi; R L T Morais; J B Pesquero; J B Calixto
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E.

Authors:  Vanessa F Merino; Mihail Todiras; Marcelo A Mori; Vicência M T Sales; Raphael G Fonseca; Vera Saul; Katja Tenner; Michael Bader; João B Pesquero
Journal:  J Mol Med (Berl)       Date:  2009-07-18       Impact factor: 4.599

7.  Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage.

Authors:  Andrew Webb; Richard Bond; Peter McLean; Rakesh Uppal; Nigel Benjamin; Amrita Ahluwalia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-03       Impact factor: 11.205

Review 8.  Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors.

Authors:  F Kuhr; J Lowry; Y Zhang; V Brovkovych; R A Skidgel
Journal:  Neuropeptides       Date:  2010-01-04       Impact factor: 3.286

9.  Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats.

Authors:  Mylène Pouliot; Sébastien Talbot; Jacques Sénécal; Florence Dotigny; Elvire Vaucher; Réjean Couture
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

10.  Plasma extravasation mediated by lipopolysaccharide-induction of kinin B1 receptors in rat tissues.

Authors:  P R Wille; R Vitor; N H Gabilan; M Nicolau
Journal:  Mediators Inflamm       Date:  2001-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.